dapsone has been researched along with AIDS-Related Opportunistic Infections in 99 studies
AIDS-Related Opportunistic Infections: Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate combined prophylaxis for Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis, 533 patients with symptomatic human immunodeficiency virus infection and/or CD4 lymphocyte counts of < 200/microL were randomized to receive dapsone/pyrimethamine (200/75 mg once weekly) or aerosolized pentamidine (300 mg every 4 weeks)." | 9.08 | Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. ( Heald, A; Hirschel, B; Iten, A; Lazzarin, A; Oertle, D; Opravil, M; Pechère, M; Praz, G; Rüttimann, S; von Overbeck, J, 1995) |
| "A 34-year-old woman with HIV infection and no other opportunistic infections presented a classic sulfone syndrome, manifested by fever, rash, hemolytic anemia, and fulminant hepatitis due to dapsone hypersensitive reaction, with a fatal outcome." | 7.69 | Dapsone therapy causing sulfone syndrome and lethal hepatic failure in an HIV-infected patient. ( Baffoe-Bonnie, H; Chalasani, P; Jurado, RL, 1994) |
| "Dapsone was more effective in the primary prophylaxis of toxoplasmic encephalitis, with six toxoplasmic encephalitis events occurring among those receiving aerosolized pentamidine, compared to none among those taking dapsone (p = 0." | 6.67 | Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. ( Barr, M; Carlo, C; Chanin, E; Gregory, G; Kiely, S; Martin, M; Thorn, M; Thornton, J; Torres, RA, 1993) |
| "To the best of our knowledge, acute generalised exanthematous pustulosis has not been reported as a reaction to dapsone in the setting of HIV." | 5.39 | Acute generalised exanthematous pustulosis induced by Pneumocystis jirovecii pneumonia prophylaxis with dapsone. ( Laws, P; Marsland, A; McQuillan, O; Vas, A, 2013) |
| "We report two cases of symptomatic hyperbilirubinemia attributed to atazanavir in conjunction with the Pneumocystis jirovecii pneumonia prophylaxis agent dapsone." | 5.38 | Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy. ( Blanton, LS; East, J, 2012) |
| "To evaluate combined prophylaxis for Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis, 533 patients with symptomatic human immunodeficiency virus infection and/or CD4 lymphocyte counts of < 200/microL were randomized to receive dapsone/pyrimethamine (200/75 mg once weekly) or aerosolized pentamidine (300 mg every 4 weeks)." | 5.08 | Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. ( Heald, A; Hirschel, B; Iten, A; Lazzarin, A; Oertle, D; Opravil, M; Pechère, M; Praz, G; Rüttimann, S; von Overbeck, J, 1995) |
| " For dapsone, among 100 patients given 100 mg daily instead of twice a week for 1 year (primary prophylaxis), seven fewer patients would develop P carinii pneumonia, but 17 more would have significant toxic reactions." | 4.79 | A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. ( Cappelleri, JC; Ioannidis, JP; Lau, J; Sacks, HS; Skolnik, PR, 1996) |
| "In a meta-analysis, we examined the efficacy of aerosolized pentamidine, trimethoprim-sulfamethoxazole, and dapsone or dapsone/pyrimethamine for the prevention of Pneumocystis carinii pneumonia and toxoplasma encephalitis in patients with HIV infection." | 4.79 | Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. ( Bucher, HC; Griffith, L; Guyatt, GH; Opravil, M, 1997) |
| "A 34-year-old woman with HIV infection and no other opportunistic infections presented a classic sulfone syndrome, manifested by fever, rash, hemolytic anemia, and fulminant hepatitis due to dapsone hypersensitive reaction, with a fatal outcome." | 3.69 | Dapsone therapy causing sulfone syndrome and lethal hepatic failure in an HIV-infected patient. ( Baffoe-Bonnie, H; Chalasani, P; Jurado, RL, 1994) |
| " Dapsone pharmacokinetic parameters were not associated with toxicity, but higher dapsone AUC was associated with decreased risk of PCP." | 2.70 | Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection. ( Bonagura, VR; Capparelli, E; Cooper, E; Jacobus, D; Lindsey, J; McIntosh, K; Mirochnick, M; Mofenson, L; Nachman, S; Spector, SA; Sullivan, JL; Xu, J; Yogev, R, 2001) |
| "Dapsone is an alternative drug for Pneumocystis carinii pneumonia (PCP) prophylaxis in individuals intolerant to trimethoprim-sulfamethoxazole (T/S)." | 2.69 | Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. ACTG 179 Study Team. AIDS Clinical Trials Group. ( Bonagura, V; Cooper, E; Jacobus, D; Kovacs, A; Lindsey, J; McIntosh, K; McNamara, J; Mirochnick, M; Mofenson, L; Nachman, S; Sacks, H; Sleasman, J; Spector, SA; Sullivan, JL; Xu, J; Yogev, R, 1999) |
| " Serial blood samples were obtained over 24 hours after dosing and analyzed for trimetrexate, dapsone, and monoacetyldapsone, and pharmacokinetic parameters were determined." | 2.69 | Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ( Chatterjee, DJ; Dubé, MP; Koda, RT; Li, WY; Sattler, FR; Stansell, JD, 1999) |
| "Rifampin was found to increase the values of clearance/bioavailability (CL/F) and volume of distribution/ bioavailability (V/F) by approximately 70%." | 2.68 | Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients. ( Bassetti, D; Casazza, R; Cruciani, M; Gatti, G; Hossein, J; Karlsson, M; Merighi, M; Travaini, S, 1996) |
| " There was no significant difference in the occurrence of serious adverse reactions (six in the dapsone and eight in the pentamidine arm)." | 2.67 | Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity. ( Hoy, JF; Kent, SJ; Lucas, CR; Pettinger, MB; Slavin, MA; Stewart, K, 1992) |
| "Dapsone was discontinued in nine (39%) patients because of adverse reactions." | 2.67 | Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant, HIV-infected individuals. ( Horowitz, HW; Jorde, UP; Wormser, GP, 1993) |
| "Standard treatments of HIV-associated Pneumocystis carinii pneumonia (PCP) consist of high dose intravenous or oral cotrimoxazole or intravenous pentamidine." | 2.67 | [Successful treatment of HIV-associated pneumocystis carinii pneumonia with dapsone plus trimethoprim]. ( Laifer, G; Rüttimann, S, 1992) |
| " The pharmacokinetics of dapsone and pyrimethamine were examined by using a population pharmacokinetic model." | 2.67 | Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia. ( Amantea, MA; Byrne, A; Davey, RT; Falloon, J; Graziani, A; Lavelle, J; Morgan, A; Ogata-Arakaki, D; Ownby, K; Polis, M, 1994) |
| "Dapsone was more effective in the primary prophylaxis of toxoplasmic encephalitis, with six toxoplasmic encephalitis events occurring among those receiving aerosolized pentamidine, compared to none among those taking dapsone (p = 0." | 2.67 | Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. ( Barr, M; Carlo, C; Chanin, E; Gregory, G; Kiely, S; Martin, M; Thorn, M; Thornton, J; Torres, RA, 1993) |
| "We report a case of P carinii infection presenting as bilateral aural polyps, otitis media and mastoiditis in human immunodeficiency (HIV)-positive patient with no history of prior or concomitant P carinii infection." | 2.41 | Pneumocystis carinii infection in bilateral aural polyps in a human immunodeficiency virus-positive patient. ( Elmahallawy, M; Horsfield, C; Praveen, CV; Terry, RM, 2002) |
| "Although the incidence of Pneumocystis carinii pneumonia (PCP) among adults infected with human immunodeficiency virus (HIV) has declined, no decline in PCP incidence has been observed among HIV-infected children, and PCP remains the most common serious opportunistic infection among both adults and children in the United States." | 2.39 | Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus. ( Feinberg, J; Hughes, WT; Navin, TR; Simonds, RJ, 1995) |
| "To the best of our knowledge, acute generalised exanthematous pustulosis has not been reported as a reaction to dapsone in the setting of HIV." | 1.39 | Acute generalised exanthematous pustulosis induced by Pneumocystis jirovecii pneumonia prophylaxis with dapsone. ( Laws, P; Marsland, A; McQuillan, O; Vas, A, 2013) |
| "We report two cases of symptomatic hyperbilirubinemia attributed to atazanavir in conjunction with the Pneumocystis jirovecii pneumonia prophylaxis agent dapsone." | 1.38 | Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy. ( Blanton, LS; East, J, 2012) |
| "Dapsone has several adverse effects in its profile that make it a potentially dangerous second-line agent." | 1.33 | Adverse reactions associated with dapsone therapy in HIV-positive patients: a case presentation and review. ( Miller, JA; Reust, R; Stephens, JR; Stroup, JS, 2006) |
| "PCR sensitivity and specificity were 100 and 86." | 1.32 | Detection of Pneumocystis carinii and characterization of mutations associated with sulfa resistance in bronchoalveolar lavage samples from human immunodeficiency virus-infected subjects. ( Carrera, P; Lazzarin, A; Scarpellini, P; Zingale, A, 2003) |
| "We describe the course of 36 AIDS patients with cerebral toxoplasmosis and present a review of clinical signs, diagnosis, therapy, and survival times." | 1.31 | [HIV-associated cerebral toxoplasmosis -- review and retrospective analysis of 36 patients]. ( Evers, S; Fischer, A; Freund, M; Grüneberg, U; Happe, S; Heese, Ch; Husstedt, IW; Kloska, S; Reichelt, D, 2002) |
| "Failures of prophylaxis against Pneumocystis carinii pneumonia (PCP) in AIDS patients do occur, but no evidence for drug resistance has yet been presented." | 1.30 | Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. ( Bartlett, MS; Cannon, M; Hossler, PA; Kazanjian, P; Lane, BR; Locke, AB; Meshnick, SR; Smith, JW, 1998) |
| " Dosing or frequency of TMP-SMX did not seem to influence risk of chemoprophylaxis failure." | 1.30 | Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators. ( Holmberg, SD; Moorman, AC; Palella, FJ; Von Bargen, JC, 1998) |
| "Dapsone is a cheap and effective prophylactic agent against P carinii in patients who cannot tolerate trimethoprim-sulfamethoxazole." | 1.30 | Bilateral upper-lobe cavitary Pneumocystis carinii pneumonia in a patient on dapsone prophylaxis. ( Anandarao, N; Dama, S; Jawahar, DA; Miarrostami, R; Sadagdhar, H, 1999) |
| " Overall results from these studies indicate patients who are eligible for PCP prophylaxis should be advised to take double-strength trimethoprim/sulfamethoxazole (TMP/SMX) on a daily basis, a dosage found more effective than thrice-weekly." | 1.30 | Optimizing PCP therapy. ( Cadman, J; Torres, G, 1997) |
| "Extrapulmonary pneumocystosis is a feature of severe immunosuppression which earlier reports have suggested is limited to patients receiving either no prophylaxis or aerosolised pentamidine." | 1.29 | Systemic Pneumocystis carinii pneumonia prophylaxis with dapsone and pyrimethamine fails to protect against extrapulmonary pneumocystosis. ( Carlin, EM; Coker, RJ; Goldin, RD; Harris, JR, 1993) |
| "Pneumocystis carinii pneumonia has been the most common life-threatening opportunistic infection in patients with acquired immunodeficiency syndrome." | 1.29 | Dilemmas in the prophylaxis of Pneumocystis carinii pneumonia. ( Glatt, AE, 1994) |
| "Bacteremia was caused by Staphylococcus aureus (23%), Pseudomonas aeruginosa (18%), Escherichia coli (16%), Streptococcus pneumoniae (14%) and others (31%)." | 1.29 | Community-acquired bacteremia in HIV-positive patients: protective benefit of co-trimoxazole. ( Edge, MD; Rimland, D, 1996) |
| "One patient had a recurrence of PCP at 4 mo, after a negative 1-mo BAL." | 1.29 | Persistence of Pneumocystis carinii in patients with AIDS receiving chemoprophylaxis. ( Antonson, S; Epstein, LJ; Meyer, RD; Mohsenifar, Z; Strigle, SM, 1994) |
| "carinii prophylaxis before the onset of AIDS: Mycobacterium avium complex disease, which developed in 33." | 1.29 | Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. ( Anderson, R; Bacellar, H; Detels, R; Hoover, DR; Kaslow, RA; Phair, J; Saah, AJ, 1993) |
| "Occurrence or recurrence of PCP." | 1.29 | Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study. ( Hoover, DR; Kingsley, LA; Peng, Y; Phair, JP; Saah, AJ; Schrager, LK; Visscher, B, 1995) |
| " Three of the 20 patients had an adverse reaction to dapsone." | 1.29 | Efficacy and safety of dapsone prophylaxis against Pneumocystis carinii pneumonia in human immunodeficiency virus-infected children. ( Noel, GJ; Stavola, JJ, 1993) |
| " Ro 11-8958, TMP, and diaveridine used at a dosage of 20 mg/kg/day with SMX were only slightly more effective than SMX used alone." | 1.29 | Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis. ( Foy, J; Steele, P; Walzer, PD; White, M, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 75 (75.76) | 18.2507 |
| 2000's | 20 (20.20) | 29.6817 |
| 2010's | 4 (4.04) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vas, A | 1 |
| Laws, P | 1 |
| Marsland, A | 1 |
| McQuillan, O | 1 |
| Ponce, CA | 1 |
| Chabé, M | 1 |
| George, C | 1 |
| Cárdenas, A | 1 |
| Durán, L | 1 |
| Guerrero, J | 1 |
| Bustamante, R | 1 |
| Matos, O | 1 |
| Huang, L | 2 |
| Miller, RF | 1 |
| Vargas, SL | 1 |
| East, J | 1 |
| Blanton, LS | 1 |
| Lim, PL | 1 |
| Zhou, J | 1 |
| Ditangco, RA | 1 |
| Law, MG | 1 |
| Sirisanthana, T | 1 |
| Kumarasamy, N | 1 |
| Chen, YM | 1 |
| Phanuphak, P | 1 |
| Lee, CK | 1 |
| Saphonn, V | 1 |
| Oka, S | 1 |
| Zhang, F | 1 |
| Choi, JY | 1 |
| Pujari, S | 1 |
| Kamarulzaman, A | 1 |
| Li, PC | 1 |
| Merati, TP | 1 |
| Yunihastuti, E | 1 |
| Messerschmidt, L | 1 |
| Sungkanuparph, S | 1 |
| Happe, S | 1 |
| Fischer, A | 1 |
| Heese, Ch | 1 |
| Reichelt, D | 1 |
| Grüneberg, U | 1 |
| Freund, M | 1 |
| Kloska, S | 1 |
| Evers, S | 1 |
| Husstedt, IW | 1 |
| Zingale, A | 1 |
| Carrera, P | 1 |
| Lazzarin, A | 2 |
| Scarpellini, P | 1 |
| James, CW | 1 |
| McNelis, KC | 1 |
| Szabo, S | 1 |
| Kazanjian, PH | 1 |
| Fisk, D | 1 |
| Armstrong, W | 1 |
| Shulin, Q | 1 |
| Liwei, H | 1 |
| Ke, Z | 1 |
| Meshnick, S | 1 |
| Stroup, JS | 1 |
| Stephens, JR | 1 |
| Reust, R | 1 |
| Miller, JA | 1 |
| Mitchell, B | 1 |
| Mahlakwane, MS | 1 |
| Ramdial, PK | 1 |
| Sing, Y | 1 |
| Calonje, E | 1 |
| Biyana, S | 1 |
| Katlama, C | 1 |
| Hoernle, EH | 1 |
| Reid, TE | 1 |
| Salmon-Ceron, D | 1 |
| Fontbonne, A | 1 |
| Saba, J | 1 |
| May, T | 1 |
| Raffi, F | 1 |
| Chidiac, C | 1 |
| Patey, O | 1 |
| Aboulker, JP | 2 |
| Schwartz, D | 1 |
| Vildé, JL | 1 |
| Saah, AJ | 2 |
| Hoover, DR | 2 |
| Peng, Y | 1 |
| Phair, JP | 1 |
| Visscher, B | 1 |
| Kingsley, LA | 1 |
| Schrager, LK | 1 |
| Podzamczer, D | 3 |
| Salazar, A | 1 |
| Jiménez, J | 2 |
| Consiglio, E | 1 |
| Santín, M | 3 |
| Casanova, A | 2 |
| Rufí, G | 1 |
| Gudiol, F | 2 |
| Opravil, M | 4 |
| Hirschel, B | 2 |
| Heald, A | 1 |
| Pechère, M | 1 |
| Rüttimann, S | 2 |
| Iten, A | 1 |
| von Overbeck, J | 1 |
| Oertle, D | 1 |
| Praz, G | 1 |
| Clumeck, N | 2 |
| Bozzette, SA | 2 |
| Finkelstein, DM | 2 |
| Spector, SA | 3 |
| Frame, P | 2 |
| Powderly, WG | 1 |
| He, W | 1 |
| Phillips, L | 1 |
| Craven, D | 1 |
| van der Horst, C | 2 |
| Feinberg, J | 3 |
| Bacellar, H | 1 |
| Phair, J | 1 |
| Detels, R | 1 |
| Anderson, R | 1 |
| Kaslow, RA | 1 |
| Epstein, LJ | 1 |
| Meyer, RD | 1 |
| Antonson, S | 1 |
| Strigle, SM | 1 |
| Mohsenifar, Z | 1 |
| Chalasani, P | 1 |
| Baffoe-Bonnie, H | 1 |
| Jurado, RL | 1 |
| Falloon, J | 1 |
| Lavelle, J | 1 |
| Ogata-Arakaki, D | 1 |
| Byrne, A | 1 |
| Graziani, A | 1 |
| Morgan, A | 1 |
| Amantea, MA | 1 |
| Ownby, K | 1 |
| Polis, M | 1 |
| Davey, RT | 1 |
| Pastor, C | 1 |
| Lumbreras, C | 1 |
| Lizasoain, M | 1 |
| Oksenhendler, E | 1 |
| Charreau, I | 1 |
| Tournerie, C | 1 |
| Azihary, M | 1 |
| Carbon, C | 1 |
| Torres, RA | 1 |
| Barr, M | 1 |
| Thorn, M | 1 |
| Gregory, G | 1 |
| Kiely, S | 1 |
| Chanin, E | 1 |
| Carlo, C | 1 |
| Martin, M | 1 |
| Thornton, J | 1 |
| Tocchetti, A | 1 |
| Tambini, R | 1 |
| Allegro, A | 1 |
| Longoni, E | 1 |
| Rinaldi, E | 1 |
| Glatt, AE | 1 |
| Barnett, ED | 1 |
| Pelton, SI | 1 |
| Mirochnick, M | 3 |
| Cooper, ER | 1 |
| Walzer, PD | 1 |
| Foy, J | 1 |
| Steele, P | 1 |
| White, M | 1 |
| Lang, W | 1 |
| Osmond, D | 1 |
| Page-Bodkin, K | 1 |
| Moss, A | 1 |
| Winkelstein, W | 1 |
| Stavola, JJ | 1 |
| Noel, GJ | 1 |
| Weintrub, PS | 1 |
| Wara, DW | 1 |
| Duliege, AM | 1 |
| Mallolas, J | 1 |
| Zamora, L | 1 |
| Gatell, JM | 1 |
| Miró, JM | 1 |
| Vernet, E | 1 |
| Valls, ME | 1 |
| Soriano, E | 1 |
| SanMiguel, JG | 1 |
| Martos, A | 1 |
| Ferrer, I | 1 |
| Jorde, UP | 1 |
| Horowitz, HW | 2 |
| Wormser, GP | 2 |
| Girard, PM | 1 |
| Landman, R | 1 |
| Gaudebout, C | 2 |
| Olivares, R | 1 |
| Saimot, AG | 1 |
| Jelazko, P | 1 |
| Certain, A | 1 |
| Boué, F | 1 |
| Bouvet, E | 1 |
| Bolao, F | 1 |
| Gudiol, GR | 1 |
| Carlin, EM | 1 |
| Coker, RJ | 1 |
| Goldin, RD | 1 |
| Harris, JR | 1 |
| Teuscher, AU | 1 |
| Theiler, R | 1 |
| Speich, R | 1 |
| Kuster, H | 1 |
| Siegenthaler, W | 1 |
| Russi, EW | 1 |
| Lüthy, R | 2 |
| Ioannidis, JP | 3 |
| Cappelleri, JC | 1 |
| Skolnik, PR | 1 |
| Lau, J | 2 |
| Sacks, HS | 1 |
| Simonds, RJ | 1 |
| Hughes, WT | 1 |
| Navin, TR | 2 |
| Richards, FO | 1 |
| Kovacs, JA | 1 |
| Luft, BJ | 1 |
| Goebel, FD | 1 |
| Bogner, JR | 1 |
| Korraa, H | 1 |
| Saadeh, C | 1 |
| Antinori, A | 3 |
| Murri, R | 3 |
| Ammassari, A | 2 |
| De Luca, A | 2 |
| Linzalone, A | 1 |
| Cingolani, A | 1 |
| Damiano, F | 1 |
| Maiuro, G | 1 |
| Vecchiet, J | 1 |
| Scoppettuolo, G | 1 |
| Safrin, S | 1 |
| Simpson, G | 1 |
| Wu, A | 1 |
| Cheung, T | 1 |
| Soeiro, R | 1 |
| Hojczyk, P | 1 |
| Black, JR | 1 |
| Weinberg, GA | 1 |
| Tamburrini, E | 1 |
| Mencarini, P | 1 |
| Visconti, E | 1 |
| Zolfo, M | 1 |
| Siracusano, A | 1 |
| Ortona, E | 1 |
| Sin, DD | 1 |
| Shafran, SD | 1 |
| Garavelli, PL | 1 |
| Gatti, G | 3 |
| Fioredda, F | 1 |
| Lorusso, C | 2 |
| Cruciani, M | 2 |
| Bassetti, D | 3 |
| Edge, MD | 2 |
| Rimland, D | 3 |
| Bundow, DL | 1 |
| Aboulafia, DM | 1 |
| Merighi, M | 1 |
| Hossein, J | 1 |
| Travaini, S | 1 |
| Casazza, R | 1 |
| Karlsson, M | 1 |
| Loy, A | 1 |
| Rossi, G | 1 |
| Deresinski, SC | 1 |
| Easterbrook, PJ | 1 |
| Bucher, HC | 1 |
| Griffith, L | 1 |
| Guyatt, GH | 1 |
| Ruggli, GM | 1 |
| Weber, R | 1 |
| Messmer, EP | 1 |
| Font, RL | 1 |
| Moll, C | 1 |
| Bernauer, W | 1 |
| Kazanjian, P | 1 |
| Locke, AB | 1 |
| Hossler, PA | 1 |
| Lane, BR | 1 |
| Bartlett, MS | 1 |
| Smith, JW | 1 |
| Cannon, M | 1 |
| Meshnick, SR | 2 |
| Moorman, AC | 1 |
| Von Bargen, JC | 1 |
| Palella, FJ | 1 |
| Holmberg, SD | 1 |
| Sackoff, J | 1 |
| McFarland, J | 1 |
| Su, S | 1 |
| Bryan, E | 1 |
| El-Sadr, WM | 1 |
| Murphy, RL | 1 |
| Yurik, TM | 1 |
| Luskin-Hawk, R | 1 |
| Cheung, TW | 1 |
| Balfour, HH | 1 |
| Eng, R | 1 |
| Hooton, TM | 1 |
| Kerkering, TM | 1 |
| Schutz, M | 1 |
| Hafner, R | 2 |
| Payen, MC | 1 |
| De Wit, S | 1 |
| Sommereijns, B | 1 |
| Cook, DE | 1 |
| Kossey, JL | 1 |
| Jawahar, DA | 1 |
| Dama, S | 1 |
| Miarrostami, R | 1 |
| Sadagdhar, H | 1 |
| Anandarao, N | 1 |
| Koda, RT | 1 |
| Dubé, MP | 1 |
| Li, WY | 1 |
| Chatterjee, DJ | 1 |
| Stansell, JD | 1 |
| Sattler, FR | 1 |
| McIntosh, K | 2 |
| Cooper, E | 2 |
| Xu, J | 2 |
| Lindsey, J | 2 |
| Jacobus, D | 2 |
| Mofenson, L | 2 |
| Yogev, R | 2 |
| Sullivan, JL | 2 |
| Sacks, H | 1 |
| Kovacs, A | 1 |
| Nachman, S | 2 |
| Sleasman, J | 1 |
| Bonagura, V | 1 |
| McNamara, J | 1 |
| Dixon, DO | 1 |
| McIntosh, M | 1 |
| Albert, JM | 1 |
| Schnittman, SM | 1 |
| Patel, SK | 1 |
| Philpott, JM | 1 |
| McPartlin, DW | 1 |
| Saillourglénisson, F | 1 |
| Chêne, G | 1 |
| Salmi, LR | 1 |
| Salamon, R | 1 |
| Winter, HR | 1 |
| Wang, Y | 1 |
| Unadkat, JD | 1 |
| Gordeuk, VR | 1 |
| Delanghe, JR | 1 |
| Langlois, MR | 1 |
| Boelaert, JR | 1 |
| Sundar, K | 1 |
| Rosado-Santos, H | 1 |
| Reimer, L | 1 |
| Murray, K | 1 |
| Michael, J | 1 |
| Chaloner, K | 1 |
| Rhame, FS | 1 |
| Sorvillo, F | 1 |
| Beall, G | 1 |
| Turner, PA | 1 |
| Beer, VL | 1 |
| Kovacs, AA | 1 |
| Kerndt, PR | 1 |
| Dorrell, L | 1 |
| McCallum, AK | 1 |
| Snow, MH | 1 |
| Ong, EL | 1 |
| Blanchet, KD | 1 |
| Cheng, B | 1 |
| Torres, G | 1 |
| Cadman, J | 1 |
| Afeltra, J | 1 |
| Meis, JF | 1 |
| Mouton, JW | 1 |
| Verweij, PE | 1 |
| Capparelli, E | 1 |
| Bonagura, VR | 1 |
| Beard, CB | 1 |
| del Rio, C | 1 |
| Lee, S | 1 |
| Pieniazek, NJ | 1 |
| Carter, JL | 1 |
| Le, T | 1 |
| Hightower, A | 1 |
| Groll, AH | 1 |
| Ritter, J | 1 |
| Müller, FM | 1 |
| Freund, YR | 1 |
| Dousman, L | 1 |
| Riccio, ES | 1 |
| Sato, B | 1 |
| MacGregor, JT | 1 |
| Mohagheghpour, N | 1 |
| Praveen, CV | 1 |
| Terry, RM | 1 |
| Elmahallawy, M | 1 |
| Horsfield, C | 1 |
| Goldie, SJ | 1 |
| Kaplan, JE | 1 |
| Losina, E | 1 |
| Weinstein, MC | 1 |
| Paltiel, AD | 1 |
| Seage, GR | 1 |
| Craven, DE | 1 |
| Kimmel, AD | 1 |
| Zhang, H | 1 |
| Cohen, CJ | 1 |
| Freedberg, KA | 1 |
| Laifer, G | 1 |
| Slavin, MA | 1 |
| Hoy, JF | 1 |
| Stewart, K | 1 |
| Pettinger, MB | 1 |
| Lucas, CR | 1 |
| Kent, SJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Three Anti-Pneumocystis Agents Plus Zidovudine for the Primary Prevention of Serious Infections in Patients With Advanced HIV Infection[NCT00000991] | Phase 3 | 600 participants | Interventional | Completed | |||
| A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Trimethoprim / Sulfamethoxazole in the Treatment of Mild-to-Moderate PCP in Patients With AIDS[NCT00000640] | Phase 3 | 290 participants | Interventional | Completed | |||
| A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides[NCT00000802] | Phase 3 | 700 participants | Interventional | Completed | |||
| Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection[NCT00000739] | Phase 1 | 96 participants | Interventional | Completed | |||
| Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole and Dapsone and Their Hydroxylamine Metabolites[NCT00000826] | Phase 1 | 48 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for dapsone and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
A background and critical analysis of the treatment of pneumocystis carinii pneumonia (PCP) in HIV/AIDS.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Anti-Inflammatory Agents; Antiprotozoa | 2007 |
Human immunodeficiency virus infection in children.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Child; Child, Preschool; Dapsone; Didanosine; Dru | 1995 |
[Current alternatives in the treatment of Pneumocystis carinii pneumonia in patients with AIDS].
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Atovaquone; Clindamycin; Dapsone; Eflornit | 1994 |
A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens.
Topics: AIDS-Related Opportunistic Infections; Dapsone; Dose-Response Relationship, Drug; Humans; Logistic M | 1996 |
Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal Agents; | 1995 |
Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus.
Topics: AIDS-Related Opportunistic Infections; Animals; Anti-Infective Agents; Cats; Dapsone; Drug Therapy, | 1995 |
[Therapy and prevention of pneumocystis carinii pneumonia].
Topics: AIDS-Related Opportunistic Infections; Animals; Antifungal Agents; Atovaquone; Clindamycin; Clinical | 1995 |
Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole.
Topics: Adrenal Cortex Hormones; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal Ag | 1996 |
Skin involvement with Pneumocystis despite dapsone prophylaxis: a rare cause of skin nodules in a patient with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Dapsone; Dermatomycoses; Humans | 1997 |
Treatment of Pneumocystis carinii pneumonia in adults with AIDS.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifunga | 1997 |
Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
Topics: Administration, Inhalation; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal | 1997 |
An unusual case of Pneumocystis carinii presenting as an aural mass.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Dapsone; Drug Therapy, Combinat | 1999 |
[Effect of dapsone on survival in HIV infected patients: a meta- analysis of finished trials].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Anti-Inflammatory Agents, Non-S | 2000 |
Iron status and the outcome of HIV infection: an overview.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-Infective Agents; be | 2001 |
[Guidelines for Prevention of Pneumocystis carinii Pneumonitis in Children and Adolescents with Cancer].
Topics: Adolescent; Age Factors; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infectiv | 2001 |
Pneumocystis carinii infection in bilateral aural polyps in a human immunodeficiency virus-positive patient.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Dapsone; Ear Neoplasms; Ear, Middle | 2002 |
24 trials available for dapsone and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. Study Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aerosols; AIDS-Related Opportunistic Infections; Dapsone; | 1995 |
Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Dapsone; Drug Administration Schedule; Drug Ther | 1995 |
Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients.
Topics: Administration, Inhalation; Adult; AIDS-Related Opportunistic Infections; Animals; Dapsone; Drug Adm | 1995 |
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.
Topics: Administration, Oral; Adult; Aerosols; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; | 1995 |
Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia.
Topics: Adult; AIDS-Related Opportunistic Infections; Biological Availability; Chromatography, High Pressure | 1994 |
Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
Topics: Adult; Aerosols; AIDS-Related Opportunistic Infections; Dapsone; Encephalitis; Female; Humans; Male; | 1993 |
Four different regimens for prevention of Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Drug Therapy, Combination; Female; Follow-Up | 1994 |
Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine.
Topics: Adult; Aerosols; AIDS-Related Opportunistic Infections; Antifungal Agents; Dapsone; Drug Therapy, Co | 1993 |
Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant, HIV-infected individuals.
Topics: Adult; AIDS-Related Opportunistic Infections; Contraindications; Dapsone; Drug Eruptions; Female; Fe | 1993 |
Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.
Topics: Adult; AIDS-Related Complex; AIDS-Related Opportunistic Infections; Dapsone; Drug Combinations; Ence | 1993 |
Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Drug Administration Schedule; Drug Therapy, C | 1993 |
Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Animals; Anti-Infe | 1995 |
Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Clindamycin; Dapsone; Double-Blind Met | 1996 |
Alternative dapsone dosage regimen for prophylaxis of Pneumocystis carinii pneumonia.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiviral Agents; Child; Child, Presch | 1996 |
Low-dose dapsone, co-trimoxazole, and survival in Pneumocystis carinii primary prophylaxis.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Dapsone; Drug Therapy, Combination; Hu | 1996 |
Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Analysis of Variance; Anti-Infective Agents; Antibioti | 1996 |
Prophylaxis for opportunistic infections among HIV-infected patients receiving medical care.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Analysis of Variance; Anti-Infective Agent | 1998 |
Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Grou
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Atovaquone; Dapsone; Female; Fo | 1998 |
A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; AIDS-Related Opportunistic Infections; Anti-Infecti | 1997 |
Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia.
Topics: Adult; AIDS-Related Opportunistic Infections; Analysis of Variance; Anti-Infective Agents; Area Unde | 1999 |
Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. ACTG 179 Study Team. AIDS Clinical Trials Group.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Child; Child, Preschool; Dapsone; Drug | 1999 |
Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antibiotics, Antitubercula | 2001 |
[Successful treatment of HIV-associated pneumocystis carinii pneumonia with dapsone plus trimethoprim].
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Ambulatory Care; Dapsone; Dose-R | 1992 |
Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity.
Topics: Administration, Intranasal; Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Bloo | 1992 |
59 other studies available for dapsone and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Acute generalised exanthematous pustulosis induced by Pneumocystis jirovecii pneumonia prophylaxis with dapsone.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; AIDS-Related Opportunistic Infections; Anti-Infec | 2013 |
High Prevalence of Pneumocystis jirovecii Dihydropteroate Synthase Gene Mutations in Patients with a First Episode of Pneumocystis Pneumonia in Santiago, Chile, and Clinical Response to Trimethoprim-Sulfamethoxazole Therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Caspofungin; Chil | 2017 |
Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia, Hemolytic; Anti-HIV Agents; Anti-Infective Age | 2012 |
Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Asia; CD4 Lymphocy | 2012 |
[HIV-associated cerebral toxoplasmosis -- review and retrospective analysis of 36 patients].
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; AIDS-Related Opportunistic Infections; Antiretrovir | 2002 |
Detection of Pneumocystis carinii and characterization of mutations associated with sulfa resistance in bronchoalveolar lavage samples from human immunodeficiency virus-infected subjects.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Bronchoalveolar Lavage Fluid; Dapsone; | 2003 |
Reinstituting trimethoprim--sulfamethoxazole in patients receiving atovaquone for Pneumocystis carinii pneumonia prophylaxis.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Atovaquone; Clinical Protocols; Dapson | 2003 |
Increase in prevalence of Pneumocystis carinii mutations in patients with AIDS and P. carinii pneumonia, in the United States and China.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Infective Age | 2004 |
Adverse reactions associated with dapsone therapy in HIV-positive patients: a case presentation and review.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Dapsone; Drug Hypersensitivity; | 2006 |
Otic pneumocystosis in acquired immune deficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Dapsone; Drug Therapy, Combinat | 2008 |
[The impact of the prevention of cerebral toxoplasmosis].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiprotozoal Agents; Brain Abs | 1995 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifunga | 1995 |
Prevention and treatment of Pneumocystis carinii pneumonia in patients infected with HIV.
Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Drug Therapy, Combination; Fees, Pharmaceutic | 1994 |
Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
Topics: Adult; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Dapsone; HIV Infections; HIV-1; | 1995 |
Primary prophylaxis against opportunistic infections in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Clotrimazole; Dapsone; Fluconazole; Humans; Mycoses; Pentamid | 1995 |
Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Candidiasis; CD4-Positive | 1993 |
Persistence of Pneumocystis carinii in patients with AIDS receiving chemoprophylaxis.
Topics: Adult; AIDS-Related Opportunistic Infections; Bronchoalveolar Lavage Fluid; Dapsone; Humans; Male; M | 1994 |
Dapsone therapy causing sulfone syndrome and lethal hepatic failure in an HIV-infected patient.
Topics: Adult; AIDS-Related Opportunistic Infections; Chemical and Drug Induced Liver Injury; Dapsone; Drug | 1994 |
Toxoplasma gondii infection in advanced HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Encephalitis; Female; Humans; Male; Middle Ag | 1994 |
Dilemmas in the prophylaxis of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Clindamycin; Dapso | 1994 |
Dapsone for prevention of Pneumocystis pneumonia in children with acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Child; Dapsone; Female; Humans; Infant; Pneumonia, Pne | 1994 |
Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.
Topics: AIDS-Related Opportunistic Infections; Animals; Dapsone; Disease Models, Animal; Dose-Response Relat | 1993 |
Population-based estimates of antiretroviral therapy and anti-Pneumocystis prophylaxis in San Francisco: 1991.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiviral Agents; Cohort Studies; Daps | 1993 |
Efficacy and safety of dapsone prophylaxis against Pneumocystis carinii pneumonia in human immunodeficiency virus-infected children.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Child; Child, Preschool; Dapsone; Humans; Infant; | 1993 |
Failure of intravenous pentamidine prophylaxis for Pneumocystis carinii pneumonia.
Topics: Administration, Inhalation; Aerosols; AIDS-Related Opportunistic Infections; Child, Preschool; Dapso | 1993 |
Hepatic and pulmonary pneumocystosis during primary prophylaxis for Pneumocystis carinii pneumonia with dapsone/pyrimethamine.
Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Drug Therapy, Combination; Humans; Liver Dise | 1993 |
Systemic Pneumocystis carinii pneumonia prophylaxis with dapsone and pyrimethamine fails to protect against extrapulmonary pneumocystosis.
Topics: Administration, Inhalation; Adult; AIDS-Related Opportunistic Infections; Dapsone; Drug Therapy, Com | 1993 |
Predictive value of bronchoalveolar lavage in excluding a diagnosis of Pneumocystis carinii pneumonia during prophylaxis with aerosolized pentamidine.
Topics: Administration, Intranasal; Adult; Aerosols; AIDS-Related Opportunistic Infections; Bronchoalveolar | 1993 |
Iron overload as a mechanism for the lowered survival in AIDS patients receiving dapsone-iron protoxalate for secondary prophylaxis of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Da | 1996 |
Imbalance between Pneumocystis carinii cysts and trophozoites in bronchoalveolar lavage fluid from patients with pneumocystosis receiving prophylaxis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal Agents; Bronchoalveo | 1996 |
Dapsone- and primaquine-induced methemoglobinemia in HIV-infected individuals.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia, Hemolytic; Anti-Infective Agents; Clindamycin; | 1996 |
[Dapsone in the prevention of HIV-related parasitosis].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiparasitic Agents; Dapsone; Drug Therapy, Combinati | 1996 |
Does dapsone increase mortality when given for prophylaxis of Pneumocystis carinii pneumonia?
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Dapsone; Humans; Pneumonia, Pneumocyst | 1996 |
Community-acquired bacteremia in HIV-positive patients: protective benefit of co-trimoxazole.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Bacteremia; Community-Acquired | 1996 |
Penetration of dapsone into lung of human immunodeficiency virus-infected children.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Bronchoalveolar Lavage Fluid; Bronchos | 1997 |
How to interpret an overview: a meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Clinical Trials as Topic; Dapsone; Dat | 1997 |
Pneumocystis carinii infection of the conjunctiva in a patient with acquired immune deficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Conjunctiva; Conjunctival Disea | 1997 |
Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Amino Acid Sequence; Anti-Infective | 1998 |
Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators.
Topics: Adult; AIDS-Related Opportunistic Infections; Ambulatory Care; Anti-Infective Agents; Antifungal Age | 1998 |
Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Algorithms; Anti-HIV Agen | 1998 |
Successful desensitization to dapsone for Pneumocystis carinii prophylaxis in an HIV-positive patient.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Dapsone; Desensitization, Immun | 1998 |
Bilateral upper-lobe cavitary Pneumocystis carinii pneumonia in a patient on dapsone prophylaxis.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Dapsone; Diagnosis, Differential; Huma | 1999 |
Atovaquone compared with dapsone to prevent Pneumocystis carinii pneumonia.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Atovaquone; Dapsone; Drug Costs; HIV I | 1999 |
Relationship between event rates and treatment effects in clinical site differences within multicenter trials: an example from primary Pneumocystis carinii prophylaxis.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Controlled Clinical Trials as Topic; D | 1999 |
Reasons for failure of prophylaxis for Pneumocystis carinii pneumonia.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal Agents; Dapsone; Humans; Pe | 1999 |
Drug-resistant Pneumocystis carinii.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Dapsone; Dihydropteroate Synthase; Dru | 1999 |
CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Aryl Hydrocarbon Hydroxylases; Catalys | 2000 |
Unusual presentation of thoracic Pneumocystis carinii infection in a patient with acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Biopsy; Dapsone; Diagnosis, Dif | 2001 |
Quantifying and documenting prior beliefs in clinical trials.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal Agents; Atovaquone; Attitud | 2001 |
Incidence and determinants of Pseudomonas aeruginosa infection among persons with HIV: association with hospital exposure.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Azithromycin; CD4 L | 2001 |
Dapsone/pyrimethamine versus aerosolized pentamidine as prophylaxis against PCP in HIV infection.
Topics: Adult; Aerosols; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents | 1995 |
Current management practices in the treatment of Pneumocystis carinii pneumonia (PCP).
Topics: AIDS-Related Opportunistic Infections; Algorithms; Anti-Infective Agents; Antifungal Agents; Dapsone | 1996 |
Preventing opportunistic infections.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Clarithromycin; Clindamycin; Clinical Trials as To | 1995 |
Optimizing PCP therapy.
Topics: Aerosols; AIDS-Related Opportunistic Infections; Antifungal Agents; Atovaquone; CD4 Lymphocyte Count | 1997 |
Adherence to PCP medications found to be low.
Topics: AIDS-Related Opportunistic Infections; Dapsone; Humans; Patient Compliance; Pneumonia, Pneumocystis; | 1998 |
Prevention of invasive aspergillosis in AIDS by sulfamethoxazole.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Aspergillosis; Aspergillus flavus; Asp | 2001 |
Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Dapsone; Dihydropteroate Syntha | 2001 |
Immunohematotoxicity studies with combinations of dapsone and zidovudine.
Topics: AIDS-Related Opportunistic Infections; Anemia; Animals; Anti-HIV Agents; Antiprotozoal Agents; Bone | 2001 |
Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiprotozoal Agents; Atovaquone; CD4 | 2002 |